RenovoRx, Inc. RNXT
1.31 USD +0.02 (+1.55%)
At closeNov 5, 2026, 7:43 AM EST
1.35 +0.04 +3.05%
Pre-market · Nov 5, 7:43 AM ET
1.27 Day range 1.37
0.701 52-week range 2.59
- YTD
- +55.95%
- 1 year
- +27.18%
- Market cap
- 59.12M
- EPS (ttm)
- -0.31
- Shares out
- 24.00M
- Forward P/E
- -3.10
- YTD return
- +55.95%
- 1-year return
- +27.18%
- Volume
- 217.51K
- Avg volume
- 803.18K
- Open
- 1.33
- Previous close
- 1.29
- Day's range
- 1.27 – 1.37
- 52-week range
- 0.701 – 2.59
- Beta
- 0.99
- Analysts
- Strong Buy
- Price target
- 5.50 (+319.8%)
- Earnings date
- Aug 13, 2024
5D -0.16 (-10.88%)
Key statistics
- Enterprise value
- 14.40M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.62M
- Total cash
- 11.74M
- Total debt
- 0
- Return on equity
- -155.12%
- Short % of float
- 0.31%
- 50-day average
- 1.14
- 200-day average
- 1.18
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 5.50 +319.8% upside
Now 1.31
- Target (low)
- 3.50
- Target (mean)
- 5.50
- Target (high)
- 9.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.12.
Financials — quick view
RNXT Revenue — quarterly 909.00K
RNXT Net income — quarterly -2.91M
RNXT EPS — quarterly -0.06
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.12 | -0.10 | +0.02 | +16.67% |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.10 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.07 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.17 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | Ascendiant Capital | main | Buy | Buy |
| Sep 12, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jun 17, 2024 | Ascendiant Capital | init | — | Buy |
| Feb 2, 2024 | Alliance Global Partners | init | — | Buy |
| Nov 15, 2023 | Maxim Group | down | Buy | Hold |
| Aug 18, 2023 | Roth MKM | main | Buy | Buy |
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- renovorx.com
News
12 Health Care Stocks Moving In Friday's After-Market Session 
RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study 
RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center 
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5 - 12 Health Care Stocks Moving In Tuesday's Intraday Session
RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure - RenovoRx Says USPTO Issues Notice Of Allowance For Patent Application Titled Methods And Apparatuses For Delivery Of Therapeutic Materials For The Treatment Of Cancer
12 Health Care Stocks Moving In Wednesday's After-Market Session 
RenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M Est - RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate
Your note
Sign in to keep a note on RNXT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGAH RAMTIN M.D. | Officer and Director | Purchase | Jan 25, 2024 | 47,460 |
| BAGAI SHAUN R. | Chief Executive Officer | Purchase | Jan 25, 2024 | 292,540 |
| MACFARLANE KIRSTEN ANGELA | Director | Purchase | Jan 25, 2024 | 40,983 |
| MARTON LAURENCE | Director | Purchase | Jan 25, 2024 | 33,634 |
| NELMS ANGELA GILL | Chief Operating Officer | Purchase | Oct 2, 2023 | 1,100 |
| SPIEGEL ROBERT J | Director | Purchase | Jan 25, 2024 | 40,983 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bank of Montreal /CAN/ | 4.06% | 975,000 | 1.24M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 1.31% | 315,192 | 400.29K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.97% | 232,937 | 295.83K | Sep 29, 2024 |
| Nixon Peabody Trust Company | 0.40% | 97,165 | 123.40K | Sep 29, 2024 |
| Millennium Management Llc | 0.34% | 82,353 | 104.59K | Sep 29, 2024 |
| Vanguard Group Inc | 0.24% | 56,737 | 72.06K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.57% | 137,402 | 174.50K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.24% | 56,737 | 72.06K | Sep 29, 2024 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.21% | 49,232 | 62.52K | Jul 30, 2024 |
| Fidelity Total Market Index Fund | 0.20% | 47,275 | 60.04K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 32,380 | 41.12K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 3,794 | 4.82K | Oct 30, 2024 |